McIntyre A M, Macgregor S, Malek M, Dunbar J A, Hamley J G, Cromarty J A
Pharmacoeconomic Research Centre, University of St Andrews, UK.
Int J Clin Pract. 1997 Jul-Aug;51(5):276-81.
Fifty-seven patients newly presenting to their GP with dyspepsia agreed to take part in a pharmacist-led clinic which tested and treated for Helicobacter pylori. Of these patients, 63% (36/57) tested positive and received eradication therapy. For 78% (28/36), eradication was successful with the first course of treatment, 89% (25/28) remaining symptom-free over the six-month follow-up. Eradication was successful for a further 17% (6/36) after a second attempt; again, these patients remained free of symptoms over the follow-up period. Thus, of the initial patients, 54% (31/57) were successfully treated, with no further symptoms. Such results had significant consequences on the expected direct cost of management per patient from a GP viewpoint. Using decision analysis it was found that H. pylori eradication for patients presenting with dyspepsia for the first time could result in considerable cost savings per patient in the long term.
57名因消化不良首次就诊于全科医生(GP)的患者同意参加由药剂师主导的诊所,该诊所对幽门螺杆菌进行检测和治疗。在这些患者中,63%(36/57)检测呈阳性并接受了根除治疗。对于78%(28/36)的患者,首次治疗疗程根除成功,89%(25/28)在六个月的随访期间无症状。第二次尝试后,又有17%(6/36)的患者根除成功;同样,这些患者在随访期间也没有症状。因此,在最初的患者中,54%(31/57)得到了成功治疗,没有进一步的症状。从全科医生的角度来看,这样的结果对每位患者预期的直接管理成本产生了重大影响。通过决策分析发现,首次出现消化不良症状的患者根除幽门螺杆菌从长期来看可为每位患者节省可观的成本。